Protein Argonaute-1 (AGO1) Antibody
260€ (50 µl)
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
935106861
info@markelab.com
name
Protein Argonaute-1 (AGO1) Antibody
category
Primary Antibodies
provider
Abbexa
reference
abx212948
tested applications
ELISA, IHC
Description
AGO1 Antibody is a Rabbit Polyclonal against AGO1.
Documents del producto
Instrucciones
Data sheet
Product specifications
| Category | Primary Antibodies |
| Immunogen Target | Protein Argonaute-1 (AGO1) |
| Host | Rabbit |
| Reactivity | Human, Mouse |
| Recommended Dilution | ELISA: 1/2000 - 1/5000, IHC: 1/50 - 1/200. Optimal dilutions/concentrations should be determined by the end user. |
| Clonality | Polyclonal |
| Conjugation | Unconjugated |
| Isotype | IgG |
| Purification | Antigen Affinity Chromatography. |
| Size 1 | 50 µl |
| Size 2 | 100 µl |
| Form | Liquid |
| Tested Applications | ELISA, IHC |
| Buffer | PBS, pH 7.4, containing 0.05% NaN3 and 40% Glycerol. |
| Availability | Shipped within 5-10 working days. |
| Storage | Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles. |
| Dry Ice | No |
| UniProt ID | Q9UL18 |
| Gene ID | 26523 |
| Alias | Q99,EIF2C,hAgo1,EIF2C1,GERP95,NEDLBAS |
| Background | Antibody anti-AGO1 |
| Status | RUO |
Descripción
AGO1 is a member of the Argonaute protein family, essential for the RNA-induced silencing complex (RISC), a key player in RNA interference (RNAi) and microRNA (miRNA)-mediated gene regulation. AGO1 primarily binds to miRNAs and facilitates the repression of target mRNA translation without significant endonucleolytic cleavage. Structurally, it contains conserved domains, including the PAZ domain, which binds the 3' end of small RNAs, and the PIWI domain, which has weak or no slicer activity in AGO1. AGO1 is expressed ubiquitously, with a role in post-transcriptional regulation in various biological processes, such as cell proliferation, differentiation, and stress responses. Dysregulation of AGO1 has been linked to diseases such as cancer and autoimmune disorders, where abnormal miRNA-mediated silencing affects critical pathways.
